amphetamine has been researched along with Agitation, Psychomotor in 13 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Mice treated with PGW5 (25 and 50mg/kg/d) for 28 days did not show toxic effects in terms of weight gain and blood-chemistry analysis." | 5.40 | A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia. ( Bidder, M; Gil-Ad, I; Kramer, M; Portnoy, M; Taler, M; Tarasenko, I; Weizman, A, 2014) |
| " In the context of bipolar disorder, amphetamine-induced hyperactivity (AIH) is a frequently used screening model for antimanic effects." | 3.91 | Questioning the predictive validity of the amphetamine-induced hyperactivity model for screening mood stabilizing drugs. ( Einat, H; Lan, A, 2019) |
| " Mice treated with PGW5 (25 and 50mg/kg/d) for 28 days did not show toxic effects in terms of weight gain and blood-chemistry analysis." | 1.40 | A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia. ( Bidder, M; Gil-Ad, I; Kramer, M; Portnoy, M; Taler, M; Tarasenko, I; Weizman, A, 2014) |
| "In case 3, the patient exhibited restlessness on the first day and one of the removed packets had ruptured." | 1.39 | Methamphetamine and amphetamine concentrations in survivors of body-packer syndrome in Japan. ( Hara, K; Hayashida, M; Mashiko, K; Ohno, Y; Saito, N; Uekusa, K; Waters, B, 2013) |
| "Amphetamine has been used in Attention Deficit Hyperactivity Disorder (ADHD), narcolepsy, and as an appetite suppressant either as the racemate or in different proportions of its enantiomers." | 1.33 | Quantitation of R-(-)- and S-(+)-amphetamine in hair and blood by gas chromatography-mass spectrometry: an application to compliance monitoring in adult-attention deficit hyperactivity disorder treatment. ( Ahlner, J; Kronstrand, R; Nyström, I; Trygg, T; Woxler, P, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (23.08) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lan, A | 1 |
| Einat, H | 1 |
| Gil-Ad, I | 1 |
| Portnoy, M | 1 |
| Tarasenko, I | 1 |
| Bidder, M | 1 |
| Kramer, M | 1 |
| Taler, M | 1 |
| Weizman, A | 1 |
| FROMMEL, E | 1 |
| FLEURY, C | 1 |
| BEGUIN, M | 1 |
| Pase, CS | 1 |
| Roversi, K | 2 |
| Trevizol, F | 1 |
| Kuhn, FT | 1 |
| Dias, VT | 1 |
| Vey, LT | 1 |
| Antoniazzi, CT | 1 |
| Barcelos, RC | 1 |
| Bürger, ME | 1 |
| Vadnie, CA | 1 |
| Ayers-Ringler, J | 1 |
| Oliveros, A | 1 |
| Abulseoud, OA | 1 |
| Choi, S | 1 |
| Hitschfeld, MJ | 1 |
| Choi, DS | 1 |
| Uekusa, K | 1 |
| Hayashida, M | 1 |
| Saito, N | 1 |
| Mashiko, K | 1 |
| Hara, K | 1 |
| Waters, B | 1 |
| Ohno, Y | 1 |
| DELPHAUT, J | 1 |
| LANZA, M | 1 |
| Nyström, I | 1 |
| Trygg, T | 1 |
| Woxler, P | 1 |
| Ahlner, J | 1 |
| Kronstrand, R | 1 |
| Brann, MR | 1 |
| Hacker, M | 1 |
| Finnerty, M | 1 |
| Ellis, J | 1 |
| Lenox, RH | 1 |
| Ehrlich, YH | 1 |
| Vanderschuren, LJ | 1 |
| Schoffelmeer, AN | 1 |
| Wardeh, G | 1 |
| De Vries, TJ | 1 |
| Balla, A | 1 |
| Koneru, R | 1 |
| Smiley, J | 1 |
| Sershen, H | 1 |
| Javitt, DC | 1 |
| Lipska, BK | 1 |
| Halim, ND | 1 |
| Segal, PN | 1 |
| Weinberger, DR | 1 |
| Pinna, GA | 1 |
| Pirisi, MA | 1 |
| Chelucci, G | 1 |
| Mussinu, JM | 1 |
| Murineddu, G | 1 |
| Loriga, G | 1 |
| D'Aquila, PS | 1 |
| Serra, G | 1 |
13 other studies available for amphetamine and Agitation, Psychomotor
| Article | Year |
|---|---|
Questioning the predictive validity of the amphetamine-induced hyperactivity model for screening mood stabilizing drugs.
Topics: Amphetamine; Animals; Anticonvulsants; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Central | 2019 |
A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia.
Topics: Alanine; Amphetamine; Animals; Antipsychotic Agents; Anxiety; Benzodiazepines; Brain; Central Nervou | 2014 |
[On the pharmacodynamics of a new neuroleptic: the alpha-isomer of 2-chloro-9-(3-dimethylaminopropylidene)-thiaxanthene HC1 or tractan. Action on the sleep centers, on motor excitation caused by nikethamide, on pentylenetetrazole, electroshock and psychom
Topics: Amphetamine; Amphetamines; Antipsychotic Agents; Central Nervous System; Electroshock; Humans; Niket | 1960 |
Chronic consumption of trans fat can facilitate the development of hyperactive behavior in rats.
Topics: Adaptation, Psychological; Akathisia, Drug-Induced; Amphetamine; Animals; Central Nervous System Sti | 2015 |
Antipsychotic-like effects of a neurotensin receptor type 1 agonist.
Topics: Amphetamine; Analysis of Variance; Animals; Antipsychotic Agents; Brain; Central Nervous System Stim | 2016 |
Methamphetamine and amphetamine concentrations in survivors of body-packer syndrome in Japan.
Topics: Adult; Amphetamine; Central Nervous System Stimulants; Crime; Foreign Bodies; Forensic Toxicology; G | 2013 |
[Effect of certain ataraxic drugs on agitations induced with amphetamine and cocaine in white mice].
Topics: Amphetamine; Amphetamines; Animals; Cocaine; Mice; Psychomotor Agitation; Seizures; Tranquilizing Ag | 1958 |
Quantitation of R-(-)- and S-(+)-amphetamine in hair and blood by gas chromatography-mass spectrometry: an application to compliance monitoring in adult-attention deficit hyperactivity disorder treatment.
Topics: Adult; Amphetamine; Central Nervous System Stimulants; Drug Monitoring; Female; Gas Chromatography-M | 2005 |
Automated analysis of stereotypic behavior induced by psychomotor stimulants.
Topics: Amphetamine; Animals; Apomorphine; Autoanalysis; Drug Interactions; Haloperidol; Humans; Male; Metho | 1983 |
Dissociable effects of the kappa-opioid receptor agonists bremazocine, U69593, and U50488H on locomotor activity and long-term behavioral sensitization induced by amphetamine and cocaine.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Amphetamin | 2000 |
Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Central Nervous System Stimulants; Corpus Stri | 2001 |
Effects of reversible inactivation of the neonatal ventral hippocampus on behavior in the adult rat.
Topics: Age Factors; Aging; Amphetamine; Analysis of Variance; Animals; Animals, Newborn; Behavior, Animal; | 2002 |
Synthesis and D(2)-like binding affinity of new derivatives of N-(1-ethyl-2-pyrrolidinylmethyl)-4,5-dihydro-1H-benzo[g]indole-3-carboxamide and related 4H-[1]benzothiopyrano[4,3-b]pyrrole and 5,6-dihydro-4H-benzo[6,7]cyclohepta[b]pyrrole-3-carboxamide ana
Topics: Amides; Amphetamine; Animals; Antipsychotic Agents; Indoles; Protein Binding; Psychomotor Agitation; | 2002 |